Evaluating Immune Therapy, Durvalumab (MEDI4736) With Tremelimumab for Metastatic, Non-transitional Cell Carcinoma of the Urinary Tract
This study is being done test to test the safety and effectiveness of durvalumab combined with tremelimumab in patients who have a rare form of cancer of the urinary tract.
Non-Transitional Cell Carcinoma of the Urothelial Tract|Small Cell of the Bladder|Adenocarcinoma of the Bladder|Squamous Cell Carcinoma of the Bladder|Metastatic Bladder Cancer
DRUG: durvalumab and tremelimumab
Overall Response Rate, by RECIST 1.1, 2 years
This study is being done test to test the safety and effectiveness of durvalumab combined with tremelimumab in patients who have a rare form of cancer of the urinary tract.